CytomX Therapeutics
TrialRedline tracks 2 clinical trials sponsored by CytomX Therapeutics: 2 Phase 2.
Company identity has not yet been verified
2Trials in this database
0Recorded changes · last 12 months
0Recruiting trials
Which trial dates moved later?
CytomX Therapeutics clinical trials we track
Check company identity sourcePhase 2 2 trials
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast CancerNCT04596150 | CX-072, CX-2009 | Completed | 2023-06-02Actual |
| PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsNCT03993379 | CX-072, Ipilimumab | Terminated | 2020-05-21Actual |
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Trial details
- Registry ID
- NCT03993379
- Drugs studied
- CX-072, Ipilimumab
Drugs in these trials
Names as written in the registry records.
- CX-072 2 trials
- CX-2009 1 trial
- Ipilimumab 1 trial
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.